Prescriber Scope of Practice for Depression in Georgia

If you’re a psychiatrist or PMHNP treating depression via telehealth, you’re navigating one of the most dynamic regulatory environments in healthcare. Federal rules are evolving, state laws vary wildly, and one misstep can mean compliance headaches or worse—disrupted patient care.

The good news? For depression providers specifically, the regulatory landscape is surprisingly favorable right now. The DEA has extended COVID-era telehealth flexibilities through December 31, 2026, meaning you can continue prescribing controlled substances (like benzodiazepines for anxiety or stimulants for comorbid ADHD) via telemedicine without an initial in-person visit. And for the SSRIs, SNRIs, and other non-controlled antidepressants that form the backbone of depression treatment? Those have never been subject to federal telehealth restrictions.

But the devil’s in the details—especially when you factor in state-specific scope of practice laws, prescribing restrictions, and the upcoming permanent DEA rules that could reshape how we practice long-term.

Let’s cut through the noise and break down what you actually need to know.

Federal DEA Rules: The Current State of Play (2025-2026)

The Ryan Haight Act and COVID-Era Flexibilities

Under normal circumstances, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires providers to conduct at least one in-person medical evaluation before prescribing any controlled substance via telemedicine. This was designed to prevent online ‘pill mills’ but created a major barrier for legitimate telepsychiatry.

During the COVID-19 Public Health Emergency, the DEA invoked an exception that allowed providers to prescribe Schedule II-V controlled substances via telehealth without that in-person visit. When the PHE ended in May 2023, the DEA didn’t let the flexibility lapse—they’ve issued four consecutive temporary extensions, the latest extending through December 31, 2026.

What this means for you: Right now, you can initiate treatment for a new patient with depression and anxiety entirely via video, including prescribing medications like:

• Benzodiazepines (Schedule IV) for acute anxiety
• Stimulants (Schedule II) for comorbid ADHD or treatment-resistant depression augmentation
• Sleep medications like zolpidem (Schedule IV)
• Buprenorphine (Schedule III) for comorbid opioid use disorder

All without ever meeting the patient face-to-face. The catch? These are temporary rules, and you need to stay alert to what’s coming next.

The Permanent Rules Taking Shape

On January 16, 2025, the DEA announced proposed permanent regulations that would formalize telehealth prescribing post-2026. The highlights:

Special Registration for Telemedicine: Providers who want to prescribe controlled substances via telehealth would apply for a new DEA registration. For Schedule III-V substances, this would be available to any qualified prescriber. For Schedule II medications (the Adderalls and Ritalins), the DEA is proposing an ‘Advanced Telemedicine Prescribing’ registration available only to:

• Board-certified psychiatrists
• Hospice/palliative care physicians
• Long-term care/nursing home physicians
• Certain pediatric specialists

This is significant: psychiatrists would explicitly be allowed to tele-prescribe Schedule II stimulants for psychiatric conditions without an in-person visit, by obtaining this special registration. The DEA is seeking public comment on whether to expand this to other specialties.

Platform Registration Requirements: For the first time, telehealth companies that facilitate controlled substance prescribing would need to register with the DEA. This is aimed at preventing the kind of questionable prescribing practices that emerged during the pandemic (think: companies prescribing high volumes of Adderall with minimal evaluation). If you work through a platform like Klarity, the company itself would need to meet these registration and reporting standards—good news for providers who want to work with compliant, legitimate platforms.

What’s NOT affected by these rules: Non-controlled medications. SSRIs, SNRIs, bupropion, mirtazapine, trazodone—the entire arsenal of first-line depression treatment—can be prescribed via telehealth under the same standard of care as in-person, with zero DEA restrictions. The federal telehealth debate is entirely about controlled substances.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Psychiatrists vs. PMHNPs

The regulatory playing field looks very different depending on your credentials and which state you’re practicing in.

Psychiatrists (MD/DO)

Your scope is straightforward: you can diagnose and treat depression, prescribe any necessary medications (controlled or not), and provide therapy. No supervision requirements, no collaborative agreements, no state-imposed limits on what you can prescribe for psychiatric conditions.

The only real constraints are general ones that apply to all physicians:

• You must be licensed in the state where the patient is located
• You need a DEA registration in each state you practice
• You must follow state PDMP requirements and e-prescribing mandates
• You’re held to the same standard of care via telehealth as in-person

Interstate Licensure Compact (IMLC): If you want to practice in multiple states, the IMLC can streamline the process. Among our priority states, Texas, Pennsylvania, and Illinois participate in the compact. Florida is also a member (though it offers a separate out-of-state telehealth registration). California and New York are NOT in the compact, so you’ll need a full license in those states—no shortcuts.

Psychiatric Mental Health Nurse Practitioners (PMHNPs)

This is where things get complicated, because NP scope of practice is determined by state law and varies dramatically.

Full Practice Authority States:

In California (as of January 2024, via AB 890), experienced PMHNPs can practice completely independently without physician supervision. You need at least 3 years/4,600 hours of experience and national certification, then you can become a ‘104 NP’ with full independent practice authority within your specialty. This includes diagnosing, treating, and prescribing for depression—including controlled substances like benzodiazepines or stimulants.

New York allows experienced NPs (those with 3,600+ hours of practice) to work without a collaborative agreement or physician oversight. This became permanent law in 2022, and it means a seasoned PMHNP in New York can run their own telepsychiatry practice completely autonomously.

Illinois offers Full Practice Authority (FPA) to APRNs who complete 4,000 hours of collaborative practice plus additional continuing education. With FPA, you can prescribe all medications independently, including Schedule II controlled substances (though Illinois does require physician consultation for extended Schedule II opioid prescriptions—less relevant for psychiatric practice).

Restricted Practice States:

Texas requires all APRNs to have a Prescriptive Authority Agreement with a physician. That physician must be licensed in Texas, and you’re required to meet regularly (at least monthly) to discuss complex cases. The physician doesn’t need to co-sign prescriptions or be present during telehealth visits, but they must be available for consultation and they’re ultimately responsible for oversight.

Florida explicitly excludes psychiatric NPs from its autonomous practice law. Only primary care NPs (family medicine, internal medicine, general pediatrics) can practice independently. If you’re a PMHNP in Florida, you must have a supervising physician and a signed protocol agreement on file with the Board of Nursing.

Pennsylvania still requires collaborative agreements for all NPs. Efforts to pass full practice authority legislation have stalled repeatedly in the state legislature, so as of 2025, PMHNPs in PA need a collaborating physician to practice and prescribe.

The practical impact: In full-practice states, you can join a platform like Klarity and see patients independently. In restricted states, you’ll need to either have your own collaborating physician already in place, or work with a platform that can pair you with a supervising psychiatrist. This affects your autonomy, but it doesn’t necessarily limit your clinical scope—you’re still managing patients and prescribing; there’s just a physician in the background administratively.

State-Specific Telehealth Prescribing Rules

Beyond scope of practice, states impose their own telehealth prescribing requirements. Here’s what matters for depression providers in the key markets:

California

• No state in-person exam requirement for prescribing via telehealth
• Must establish a valid patient relationship (can be done via live video)
• Strong telehealth parity laws requiring insurance coverage equivalent to in-person
• Must check the state PDMP (CURES) when prescribing controlled substances
• Audio-only telehealth was allowed during COVID for mental health; video is preferred now but phone may be acceptable if it meets standard of care
• Not in IMLC, so out-of-state psychiatrists need a full CA license (no telehealth-specific license available)

Texas

• A valid physician-patient relationship can be established via audio-visual telemedicine—no in-person visit required for initial consult
• Chronic pain treatment with controlled substances via telehealth is prohibited unless you’ve seen the patient in-person or via video within 90 days and meet other stringent requirements. This doesn’t affect routine depression/anxiety treatment, but if you’re managing a patient with depression who also has chronic pain on opioids, be cautious.
• Texas medical board rules emphasize video over audio-only for new patient encounters (phone-only generally insufficient)
• Participates in IMLC for physicians
• NPs require prescriptive authority agreement with a Texas physician; no exceptions

Florida

• Allows out-of-state providers to register for a Florida Telehealth Registration (renewable every 2 years) without obtaining full licensure
• Critical prescribing rule: Schedule II controlled substances cannot be prescribed via telehealth in Florida, EXCEPT for: psychiatric disorders, inpatient care, hospice, or nursing home residents. This exception explicitly allows psychiatrists to tele-prescribe stimulants and other Schedule II meds for ADHD, treatment-resistant depression, and other psychiatric conditions.
• Schedule III-V can be prescribed via telehealth without restriction
• Must obtain patient consent and verify identity
• Must check Florida’s PDMP (E-FORCSE) before prescribing controlled substances
• Psychiatric NPs cannot practice independently in Florida (must have supervising physician)

New York

• No state in-person exam requirement
• Strong telehealth parity laws
• Allowed audio-only telehealth for mental health during COVID; many provisions extended
• Mandatory e-prescribing for all prescriptions (very strict enforcement)
• Must register with NY’s Prescription Monitoring Program
• Not in IMLC; out-of-state psychiatrists need full NY license
• Experienced NPs (3,600+ hours) can practice independently without collaborative agreement

Pennsylvania

• No comprehensive telehealth statute, but Department of State FAQs confirm telehealth is allowed within scope of practice if it meets standard of care
• No state in-person exam requirement
• Mandatory e-prescribing for controlled substances
• NPs must have collaborative agreement with physician
• Participates in IMLC for physicians (joined 2021)
• State boards emphasize having emergency protocols in place for tele-mental health (e.g., how to activate local emergency services if patient is suicidal)

Illinois

• Telehealth Expansion Act (2021) established permanent telehealth parity and prohibits insurers from requiring prior in-person visits
• No state in-person exam requirement
• Allows telehealth from any location (including patient’s home)
• Full Practice Authority available for experienced APRNs (4,000 hours + additional education)
• Audio-only allowed for behavioral health when appropriate
• Must use Illinois PDMP and e-prescribe controlled substances
• Participates in IMLC for physicians
• FPA NPs need physician consultation process for chronic high-dose opioid prescriptions (less relevant to psych practice)

The Economics of Telehealth Practice: Why Platform Models Make Sense

Here’s what nobody talks about: DIY marketing for a telepsychiatry practice is expensive and slow.

If you’re thinking about building your own telehealth patient base through SEO, Google Ads, or directory listings, the reality check:

SEO takes 6-12 months of consistent investment (often $2,000-4,000/month for content, technical optimization, and link building) before you see meaningful patient flow. Most solo providers don’t have the expertise or patience.

Google Ads for mental health keywords run $15-40+ per click, and most clicks don’t convert to booked patients. Factor in the cost of landing page optimization, ad testing, form abandonment, no-shows from cold leads, and you’re looking at $200-400+ per booked patient once you account for your total ad spend and wasted clicks.

Directory listings like Psychology Today charge monthly fees ($30-50/month) AND you’re competing with hundreds of other providers on the same search results page. Zocdoc charges per booking ($35-100+ depending on specialty) plus monthly subscription fees. The economics add up quickly when you’re trying to fill a schedule.

Total realistic patient acquisition cost through DIY marketing—when you factor in agency/consultant fees, ad spend, staff time to handle and qualify leads, no-show rates, and failed campaigns—typically runs $200-500+ per qualified psychiatric patient. And that’s assuming you have the marketing expertise, budget, and months of runway to test and optimize.

The platform model flips this equation: Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you. Platforms like Klarity use a pay-per-appointment model where you pay a standard listing fee per new patient lead. The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty, availability, and insurance acceptance
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (EMR, video platform, billing)—no separate platform costs
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

This is the smart economic choice for most providers, especially those starting out or scaling: you remove the financial risk of marketing entirely and get guaranteed ROI. DIY marketing can eventually be cost-effective IF you have the budget, expertise, and patience—but for providers who want to focus on clinical work rather than becoming marketing experts, a platform that handles patient acquisition is the logical move.

Looking Ahead: What to Monitor

The regulatory environment is moving in a favorable direction for telepsychiatry, but there are key developments to watch:

1. DEA’s Final Rules (Expected Late 2026)The proposed special registration system will likely be finalized before the current extension expires. Pay attention to:

• Registration requirements and costs
• Whether PMHNPs are included in Schedule II teleprescribing (current proposal limits it to psychiatrists)
• Reporting requirements for platforms and individual providers
• Any limits on prescription quantities or follow-up timelines

2. State Scope of Practice LegislationSeveral states are considering NP independence bills:

• Pennsylvania has SB 25 pending (would grant FPA to experienced NPs)
• Texas regularly debates APRN scope expansion (hasn’t passed yet)
• Florida’s exclusion of psychiatric NPs from autonomous practice may face challenges

3. Interstate Licensure ExpansionMore states are joining compacts:

• Illinois enacted an APRN Compact in 2023 (not active yet; needs more member states)
• Additional states considering IMLC membership
• Watch for streamlined multi-state telehealth licensing options

Practical Compliance Checklist

For all depression providers practicing via telehealth:

✓ Licensure: Confirm you’re licensed (or have valid telehealth registration) in every state where your patients are located at the time of the consult

✓ DEA Registration: Maintain current DEA registration in each state where you prescribe controlled substances

✓ PDMP Compliance: Check your state’s prescription drug monitoring program before prescribing controlled substances (required in nearly all states)

✓ E-Prescribing: Use DEA-compliant e-prescribing software for controlled substances where mandated (TX, PA, NY, IL all require it)

✓ Informed Consent: Document patient consent for telehealth services, including discussion of limitations, emergency protocols, and privacy

✓ Standard of Care: Conduct thorough psychiatric evaluations via video (mental status exam, suicide risk assessment, PHQ-9/GAD-7 screening tools, etc.)—same rigor as in-person

✓ Documentation: Chart notes should meet the same standards as in-person visits; document why telehealth is appropriate for the patient’s condition

✓ Emergency Protocols: Know how to activate local emergency services if a patient is in crisis during a tele session

✓ Platform Compliance: If working through a telehealth platform, verify they’re compliant with state laws and upcoming DEA registration requirements

Additional for PMHNPs in restricted states:

✓ Collaborative Agreement: Ensure you have a current, signed collaborative or supervisory agreement with a physician licensed in the state where you’re practicing

✓ Physician Availability: Maintain required consultation schedule (e.g., monthly meetings in Texas)

✓ Protocol Documentation: Keep protocols on file with state nursing board where required

The Bottom Line

If you’re a depression provider, telehealth regulations are more favorable now than they’ve ever been—and the trend is toward expansion, not restriction. Federal DEA rules allow you to prescribe controlled substances via telemedicine through at least 2026, and the proposed permanent rules would formalize psychiatrists’ ability to do so long-term with a special registration.

State laws vary widely, but the key markets (CA, NY, IL, TX, FL, PA) all permit telehealth prescribing when done appropriately. The biggest variable is NP scope of practice: if you’re a PMHNP, your autonomy depends heavily on which state you’re in.

The economic reality is this: building your own telehealth patient base from scratch is expensive and time-consuming. Platforms that handle patient acquisition and provide infrastructure make the economics work—you pay only when patients book, and you skip the months of marketing experimentation and financial risk.

The regulatory landscape will continue evolving, but one thing is clear: telepsychiatry for depression isn’t going anywhere. If anything, policymakers are working to expand access while adding guardrails against abuse. Providers who stay compliant, document thoroughly, and work with legitimate platforms will be well-positioned for the long term.

Ready to skip the marketing headache and start seeing patients? Explore how Klarity’s provider network handles patient acquisition, credentialing, and compliance so you can focus on clinical care—without the upfront costs or regulatory uncertainty of going it alone.

Frequently Asked Questions

Can I prescribe antidepressants to a new patient via telehealth without ever meeting them in person?

Yes. Non-controlled antidepressants (SSRIs, SNRIs, bupropion, mirtazapine, etc.) are not subject to DEA telehealth restrictions. As long as you conduct an appropriate evaluation via video (or audio if your state permits and it meets standard of care), establish a valid patient relationship, and document your clinical reasoning, you can prescribe depression medications entirely via telehealth.

What about controlled substances like benzodiazepines or stimulants?

Under current federal rules (extended through December 31, 2026), you can prescribe Schedule II-V controlled substances via telehealth without an in-person visit, as long as you conduct a proper evaluation and meet all other prescribing requirements (DEA registration, PDMP check, etc.). This means you can manage a patient’s anxiety with benzodiazepines or prescribe stimulants for comorbid ADHD entirely via video visits. After 2026, new permanent DEA rules will likely require a special telemedicine registration, but the ability to prescribe these medications via telehealth should continue for qualified providers (especially psychiatrists).

Do I need to be licensed in the state where I’m located or where the patient is located?

The patient’s location. Telehealth doesn’t change medical licensure requirements—you must be licensed in the state where the patient is physically located at the time of the consultation. If you’re in New York seeing a patient in California, you need a California license (or valid telehealth registration if the state offers one, like Florida does).

What’s the difference between practicing via the Interstate Medical Licensure Compact vs. getting individual state licenses?

The IMLC streamlines the process of obtaining multiple state licenses. Instead of applying to each state separately with redundant paperwork, you apply through the compact and can get expedited licenses in all member states. You still end up with full individual state licenses (not a special ‘compact license’), but the process is faster and cheaper. Among priority states, Texas, Pennsylvania, Illinois, and Florida participate in the IMLC. California and New York do not.

Can PMHNPs prescribe the same medications as psychiatrists?

Clinically, yes—PMHNPs are trained to manage depression and can prescribe the same medications. Legally, it depends on the state. In full-practice states (CA, NY, IL with FPA), PMHNPs can prescribe all medications including controlled substances independently. In restricted states (TX, FL, PA), PMHNPs need a collaborative agreement with a physician and may face additional limits on Schedule II prescribing. The medications themselves are the same; the regulatory requirements differ.

Are there any depression medications I can’t prescribe via telehealth?

Not from a federal standpoint, with one exception: esketamine (Spravato) for treatment-resistant depression. This is a Schedule III nasal ketamine spray that FDA/REMS rules require be administered under supervision in a certified medical setting (patient cannot take it home). You can do the psychiatric evaluation and prescribing decision via telehealth, but the actual administration must happen at a REMS-certified clinic with monitoring. All other depression medications—including off-label treatments like atypical antipsychotics or anticonvulsants—can be prescribed via telehealth if clinically appropriate.

What if I’m prescribing for a patient with both depression and chronic pain?

Be careful here, especially in Texas. Texas explicitly prohibits treating chronic pain with controlled substances via telehealth unless you’ve had an in-person or video visit within 90 days and meet other stringent requirements. If you’re a psychiatrist managing a patient’s depression who also happens to be on long-term opioids for chronic pain, you may need to coordinate with their pain management physician or ensure you meet Texas’s specific requirements. For depression treatment itself (even if the patient has pain), you’re fine—the restriction is specifically about treating the pain with controlled substances, not treating depression in someone who has pain.

How do I verify if my telehealth platform is compliant with upcoming DEA registration requirements?

Ask directly. Any legitimate platform should be able to show you:

• Their plan to register with DEA once the permanent rules are finalized
• How they verify provider credentials and DEA registrations
• What controls they have in place to prevent inappropriate prescribing
• How they handle PDMP integration and prescription monitoring

If a platform is vague about compliance or doesn’t seem aware of the DEA’s proposed registration requirements for telehealth companies, that’s a red flag. Established platforms like Klarity are already preparing for these requirements and building the infrastructure to meet them.

Can I use audio-only (phone) telehealth for depression evaluations and prescribing?

It depends on the state and the clinical situation. During COVID, many states (including California, New York, Illinois) allowed audio-only telehealth for mental health services, and some have extended those allowances. However, best practice is to use video whenever possible, especially for:

• Initial evaluations (mental status exam is more thorough with visual observation)
• Prescribing controlled substances (some states specifically require video for this)
• Patients with complex presentations or safety concerns

If you do use audio-only, document why video wasn’t feasible (e.g., patient lacks smartphone, internet bandwidth issues) and why the standard of care could still be met. Some states like Texas emphasize video over audio for establishing new patient relationships.

What happens if the DEA doesn’t finalize permanent rules before December 31, 2026?

Most likely, they’ll issue another temporary extension to avoid disrupting care for millions of patients currently receiving telehealth prescriptions. The DEA and HHS have shown a pattern of extending the rules rather than letting them lapse—they’ve done it four times already. That said, providers shouldn’t count on this. If the extension expired without new rules, prescribing controlled substances to patients you’ve never seen in person would technically violate the Ryan Haight Act. Realistically, advocacy groups (APA, AMA, etc.) would push hard for continued flexibility, and Congress could also act to permanently authorize telehealth prescribing. Stay tuned to DEA announcements in late 2026.

Citations & References

1. U.S. Department of Health and Human Services. (2026, January 2). HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. Press Release. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (2025, January 16). DEA Announces Three New Telemedicine Rules to Continue Open Access to Medical Care and Strengthen Safeguards. Press Release. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47 – Use of Telehealth to Provide Services. Florida Legislature Online Sunshine. https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Texas Administrative Code Title 22, Part 9, Rule §174.5 – Telemedicine Issuance of Prescriptions. Texas Secretary of State eLaws. https://txrules.elaws.us/rule/title22chapter174sec.174.5

5. California Board of Registered Nursing. (2023). AB 890 Implementation – Nurse Practitioner Practice Without Standardized Procedures. https://www.rn.ca.gov/practice/ab890.shtml

This content is for informational purposes and does not constitute legal or medical advice. Providers should consult with legal counsel and their state licensing boards for guidance specific to their practice. Regulations current as of February 2026.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=These%20rules%20are%20a%20result,temporary%20rule%20until%20December%202025
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=is%20accessible%20for%20medical%20care,is%20being%20prescribed%20controlled%20medication
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%20law%20previously%20allowed,based%20on%20only
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,person%20setting
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,be
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,through%20a%20telemedicine%20medical%20service